<SEC-DOCUMENT>0001724521-26-000032.txt : 20260505
<SEC-HEADER>0001724521-26-000032.hdr.sgml : 20260505
<ACCEPTANCE-DATETIME>20260505160918
ACCESSION NUMBER:		0001724521-26-000032
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260505
DATE AS OF CHANGE:		20260505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38419
		FILM NUMBER:		26943128

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 694-6200

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rcus-20260505.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ddb46-f8c8-790c-809f-ed4e4a8549d1,g:570cf75d-5d9f-4510-900f-7a086033b77e,d:b3ef8af80fb2453ba845516436f95737-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rcus-20260505</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001724521</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rcus-20260505.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-28</xbrli:startDate><xbrli:endDate>2025-10-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib3ef8af80fb2453ba845516436f95737_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May&#160;5, 2026</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Arcus Biosciences, Inc.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38419</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">47-3898435</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(State or Other Jurisdiction</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">of Incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">3928 Point Eden Way</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Hayward</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94545</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">510</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">694-6200</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:40.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Trading</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">RCUS</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div><div id="ib3ef8af80fb2453ba845516436f95737_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-23">May&#160;5, 2026</ix:nonNumeric>, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months ended March&#160;31, 2026. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div id="ib3ef8af80fb2453ba845516436f95737_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2026q18kexhibit991.htm">Press release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2026q18kexhibit991.htm">May 5, 2026</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div><div id="ib3ef8af80fb2453ba845516436f95737_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:46.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-24">May&#160;5, 2026</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Terry Rosen, Ph. D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Terry Rosen, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a2026q18kexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i556f6ded4fab461d86c878160ce8c450_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:6pt"><img alt="img230044022_0a.jpg" src="img230044022_0a.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:143px"></div><div style="margin-top:30pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">May&#160;5, 2026</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Arcus outlines development strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including the potential to become the first HIF-2a inhibitor-based tyrosine kinase inhibitor (TKI)-free regimen in the first-line (1L) setting</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 PEAK-1 study is enrolling in immunotherapy (IO)-experienced patients with ccRCC, with enrollment completion and the initiation of a 1L Phase 3 study, both expected by year-end 2026</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Arcus selected its first inflammation program clinical candidate AB102, an MRGPRX2 antagonist, which is expected to enter the clinic in the third quarter of 2026&#59; its preclinical profile will be presented in an oral presentation at the Society for Investigative Dermatology Annual Meeting in May</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">With $876&#160;million in cash, cash equivalents and marketable securities at quarter-end, Arcus is well positioned to advance casdatifan aggressively, with cash runway until at least the second half of 2028 </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">HAYWARD, Calif. &#8211; (BUSINESS WIRE) &#8211;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Arcus Biosciences, Inc. (NYSE&#58;RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today reported financial results for the first quarter ended March&#160;31, 2026 and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Arcus is entering a new era, with a clear path for casdatifan to be both first and best in the first-line setting, and a portfolio of wholly owned molecules for inflammation and immunology that provide a new strategic optionality as they move into and through development,&#34; said Terry Rosen, Ph.D., chief executive officer of Arcus. &#34;Our highest priority is to establish casdatifan as a foundational standard of care in kidney cancer so that patients have the opportunity to benefit from casdatifan-based regimens across lines of treatment.&#8221; </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arcus is focused on completing enrollment for PEAK-1 and initiating a Phase 3 study in the 1L setting, where casdatifan has the potential to become the first HIF-2a inhibitor-based, TKI-free option, by year-end 2026.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Casdatifan (HIF-2a inhibitor)</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Casdatifan Development Program&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arcus&#8217;s development strategy is designed to generate evidence to secure casdatifan as a backbone therapy in ccRCC so that every patient has the opportunity to benefit from casdatifan across each line of therapy over the course of their care. The company is aggressively executing on a holistic strategy to embed casdatifan into the treatment paradigm, including in combination with the most commonly used regimen in the 1L setting, anti-PD-1 plus anti-CTLA-4. Arcus is now enrolling a cohort in the Phase 1&#47;1b ARC-20 study to generate the dataset that will support the initiation of the corresponding Phase 3 study at year-end 2026. Arcus&#8217;s choice of combination partners has been designed to complement this casdatifan-IO regimen, which has the opportunity to be the first and only such HIF-2a inhibitor-based TKI-sparing 1L therapy, with consecutive treatments with casdatifan-containing regimens in first-, second-, and third-line-plus settings. In this context, Arcus will also begin to evaluate casdatifan plus TKI-containing regimens in 1L and late-line settings, the latter in both HIF-2a inhibitor-experienced and HIF-2a inhibitor-naive patients. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">IO-experienced ccRCC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#58; Enrollment in PEAK-1, the global Phase 3 study evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced metastatic ccRCC, is accelerating, and Arcus is on track to complete enrollment by year-end 2026.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">1L ccRCC&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arcus has been focused on the evaluation of casdatifan-based TKI-free regimens, which have demonstrated a consistently low rate of primary progression across all cohorts and settings evaluated to date. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.11pt;text-decoration:underline">Most notably, casdatifan plus zimberelimab (anti-PD-1) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">showed a primary progression rate of 7% (2 of 30 patients), comparing quite favorably to published rates observed with anti-PD-1 monotherapy or ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) in the 1L setting. This ARC-20 cohort is fully enrolled.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.11pt;text-decoration:underline">A cohort evaluating casdatifan plus zimberelimab and ipilimumab</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in ARC-20 is currently enrolling with the purpose of supporting Arcus&#8217;s first Phase 3 study in the 1L setting. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Planned Data Readouts&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arcus expects to have multiple data readouts for casdatifan in 2026&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">More mature overall response rate data and initial progression-free survival data for approximately 45 patients treated in the ARC-20 cohort evaluating casdatifan plus cabozantinib in the IO-experienced setting will be presented at an investor event or at a medical conference. All patients will have had at least 12 months of follow-up.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Initial data from the ARC-20 cohorts evaluating casdatifan in early-line settings, including the cohort evaluating casdatifan plus zimberelimab in 1L ccRCC.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Updated data from ARC-20 late-line monotherapy cohorts including overall survival (OS) data.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Quemliclustat (small-molecule CD73 inhibitor</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">)</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Enrollment was completed for PRISM-1, a Phase 3 trial of quemliclustat combined with gemcitabine&#47;nab-paclitaxel versus gemcitabine&#47;nab-paclitaxel in 1L metastatic pancreatic ductal adenocarcinoma, in September 2025. Results from this study are expected in the first half of 2027. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Domvanalimab (Fc-silent anti-TIGIT antibody) plus Zimberelimab (anti-PD-1 antibody)</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Status Update&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">In April 2026, Arcus announced the discontinuation of the Phase 3 STAR-121 study evaluating domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a 1L treatment for metastatic non-small cell lung cancer (NSCLC), based on the recommendation from the Independent Data Monitoring Committee following its review of data from a pre-planned futility analysis. At the futility analysis, the domvanalimab-based combination did not improve OS relative to that observed with pembrolizumab plus chemotherapy. STAR-121, along with the Phase 2 EDGE-Lung study, will be discontinued.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.11pt">STAR-121 also evaluated zimberelimab plus chemotherapy as an exploratory endpoint. Zimberelimab plus chemotherapy performed consistently with respect to OS as compared to pembrolizumab plus chemotherapy.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Emerging I&#38;I Portfolio </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">AB102, a highly selective, oral MRGPRX2 antagonist and potential best-in-class treatment for atopic dermatitis and chronic spontaneous urticaria, is expected to enter the clinic in the third quarter of 2026. </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.11pt">In May, Arcus will present the preclinical profile for AB102 in an oral presentation at the Society for Investigative Dermatology Annual Meeting, highlighting its ability to fully block MRGPRX2-dependent degranulation and transcriptional activation in LAD2 and primary skin mast cells and its inhibition of all common human MRGPRX2 variants.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.11pt">Clinical development will begin with a first-in-human healthy volunteer study followed by a proof-of-concept study, with potential for proof-of-concept data in early 2027.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Arcus has selected a development candidate for an oral small-molecule TNF inhibitor, a potential treatment for rheumatoid arthritis, psoriasis and inflammatory bowel disease, and expects it to enter the clinic in early 2027. </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.11pt">The molecule is designed to selectively block TNFR1 signaling. It is believed that this could lead to better safety and efficacy than those of approved anti-TNF antibodies that block both TNFR1 and </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">TNFR2 signaling, the latter of which can paradoxically lead to an inflammatory response in some patients.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Arcus has also selected an orally active small-molecule antagonist of CCR6 as a development candidate for potential treatment of psoriasis and expects it to enter the clinic in the first half of 2027.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results for First Quarter 2026&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Cash, Cash Equivalents and Marketable Securities </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">were $876&#160;million as of March&#160;31, 2026, compared to $1.0&#160;billion as of December 31, 2025. The decrease during the period is primarily due to the use of cash in our research and development activities. Based on our existing business plan, we believe that our cash, cash equivalents and marketable securities will be sufficient to fund our planned level of operations until at least the second half of 2028. We also expect to end 2026 with approximately $600 million in cash.</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Revenues </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">were $17&#160;million for the first quarter 2026, compared to $28&#160;million for the same period in 2025. The decrease in revenue was primarily driven by lower development services revenue from the Gilead collaboration. Revenues reflect the recognition of payments previously received from our collaboration partners as we satisfy underlying performance obligations over time, and fluctuate each period based on our estimated progress toward completing those obligations rather than on the timing of cash receipts. Arcus expects to recognize GAAP revenue of between $50 million and $65 million for the full year 2026.</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Research and Development (R&#38;D) Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> were flat for the first quarter 2026, with (i) late-stage development programs increasing due to our investment in casdatifan and our Phase 3 PRISM-1 study for quemliclustat, partially offset by the wind-down of studies related to domvanalimab, (ii) early-stage development activities decreasing primarily due to the absence of prior-year Phase 2 study costs for domvanalimab, and (iii) partnership reimbursements decreasing, primarily due to Gilead-led activities representing a larger share of total joint development costs and a shift towards programs fully funded by us. Non-cash stock-based compensation expense was $9&#160;million for the first quarter 2026, compared to $8&#160;million for the same period in 2025. For the first quarters 2026 and 2025, Arcus recognized gross reimbursements of $19&#160;million and $38&#160;million, respectively, for shared expenses from its collaborations. R&#38;D expenses by quarter may fluctuate due to the timing of clinical manufacturing and standard-of-care therapeutic purchases with a corresponding impact on reimbursements. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect R&#38;D expenses to decline in the near term relative to what we have incurred as we wind down studies for domvanalimab. Streamlining initiatives we have undertaken across our R&#38;D operations in connection with this wind-down, together with efficiencies we are pursuing across our programs outside the Gilead collaboration, are expected to further reduce costs. These decreases will be partially offset by our increased investment in the development of casdatifan and advancement of our small-molecule inflammation and immunology programs.</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">General and Administrative (G&#38;A) Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> were $29&#160;million for the first quarter 2026, compared to $28&#160;million for the same period in 2025. The increase was primarily due to an increase in non-cash stock-based compensation, which was primarily attributable to a separation agreement with an officer. Non-cash stock-based compensation expense was $10&#160;million for the first quarter 2026, compared to $8&#160;million for the same period in 2025.</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Net Loss</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> was $128&#160;million for the first quarter 2026, compared to $112&#160;million for the same period in 2025.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call Information&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arcus will host a conference call and webcast today, May 5, 2026, at 1&#58;30 PM PT&#47;4&#58;30 PM ET to discuss its first-quarter 2026 financial results and pipeline updates. To access the call, please dial +1 (585) 542-9983 (local) or +1 (833) 461-5787 (toll-free), using Meeting ID&#58; 304747896. Participants may also register for the call online using the following link&#58; https&#58;&#47;&#47;events.q4inc.com&#47;attendee&#47;304747896. To access the live webcast and accompanying slide presentation, please visit the &#8220;Investors &#38; Media&#8221; section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">About Arcus Biosciences</font></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for the treatment of cancer and inflammatory and autoimmune diseases. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of its late-stage portfolio of first- and&#47;or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences&#8217; clinical and preclinical programs, please visit www.arcusbio.com.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to,  statements regarding Arcus&#8217;s development strategies and opportunities, including the potential for casdatifan to become the first and only HIF-2a inhibitor-based TKI-free regimen in the first line setting and plans to secure casdatifan as the backbone therapy in ccRCC&#59; the timing and achievement of milestones, including the completion of enrollment in PEAK-1, the initiation of the next Phase 3 study for casdatifan, and the advancement of AB102 into the clinic&#59; the progression into the clinic of additional molecules from Arcus&#8217;s inflammation and immunology programs&#59; the timing of future data presentations&#59; and expectations regarding the decline in its operating expenses, year-end cash balance and its anticipated cash runway. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus&#8217;s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, risks associated with&#58; Arcus&#8217;s ability to manage the breadth and pace of its development plans for casdatifan&#59; the unexpected emergence of adverse events or other undesirable side effects with casdatifan&#59; difficulties or delays in initiating, enrolling and completing clinical trials, including due to regulatory review, site activation, patient identification or enrollment, or manufacturing and supply constraints of investigational or standard-of-care products for such clinical trials&#59; interim data not being guarantees of future data or replicated in other studies evaluating casdatifan, including the Phase 3 PEAK-1 study&#59; adverse data from toxicology studies that affect Arcus&#8217;s ability to advance development candidates from its immunology and inflammation programs&#59; the risk that the preclinical profiles of Arcus&#8217;s development candidates may not translate in clinical trials&#59; changes in the competitive landscape for Arcus&#8217;s programs&#59; the inherent uncertainty associated with pharmaceutical product development and clinical trials&#59; and risks associated with Arcus&#8217;s ability to accurately forecast financial results and changes in Arcus&#8217;s operating plans. Risks and uncertainties facing Arcus are described more fully in the &#8220;Risk Factors&#8221; section of Arcus&#8217;s most recent periodic report filed with the U.S. Securities and Exchange Commission (SEC) and in other filings that Arcus makes with the SEC from time to time, which are available at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release, except to the extent required by law.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Investor &#38; Media Inquiries&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Holli Kolkey<br>VP of Corporate Affairs<br>(650) 922-1269<br></font><font style="color:#0563c1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">hkolkey&#64;arcusbio.com</font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Maryam Bassiri</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Director of Corporate Affairs</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(510) 406-8520</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">mbassiri&#64;arcusbio.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div><div id="i556f6ded4fab461d86c878160ce8c450_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">(In millions, except per share amounts)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Revenues&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">License and development services</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Other collaboration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">17&#160;</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">28&#160;</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">122&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">122&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">General and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">29&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">151&#160;</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">150&#160;</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Loss from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(134)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(122)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-operating income (expense)&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Interest and other income, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Interest expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(3)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total non-operating income, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">6&#160;</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Loss before income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(128)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(112)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Income tax expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Net loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(128)</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(112)</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Net loss per share&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(1.02)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(1.14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Shares used to compute net loss per share&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">125.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">98.4</font></td></tr></table></div><div id="i556f6ded4fab461d86c878160ce8c450_7"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Selected Consolidated Balance Sheet Data</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">(In millions)</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br>2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">876&#160;</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">1,010&#160;</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">997&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">1,139&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">473&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">508&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">524&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">631&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Derived from the audited financial statements for the year ended December&#160;31, 2025, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February&#160;25, 2026.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rcus-20260505.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ddb46-f8c8-790c-809f-ed4e4a8549d1,g:570cf75d-5d9f-4510-900f-7a086033b77e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rcus="http://arcusbio.com/20260505" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://arcusbio.com/20260505">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20260505_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20260505_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://arcusbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rcus-20260505_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ddb46-f8c8-790c-809f-ed4e4a8549d1,g:570cf75d-5d9f-4510-900f-7a086033b77e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019ddb46-f8c9-7070-b850-47f0603fa882_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019ddb46-f8c9-756b-a9cf-46985cd9ac36_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019ddb46-f8c9-7e66-ba85-25ec8e8b86e0_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019ddb46-f8c9-7584-b557-a2d01c6d8755_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019ddb46-f8c9-7b1e-bbe7-d492579dbb9e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019ddb46-f8c9-7bfc-b505-f9a4479fdd68_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_019ddb46-f8c9-7359-bd63-01f4b1915a1a_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019ddb46-f8c9-72d6-990c-f4f5ecb7a318_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019ddb46-f8c9-7df7-892e-e465e5730619_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019ddb46-f8c9-7714-b9dc-89fd5e1bb34a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019ddb46-f8c9-74ec-bc52-a2d26de8de9d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019ddb46-f8c9-74b5-a5a9-8728f7946618_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019ddb46-f8c9-7a9e-9e59-690f7742f452_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019ddb46-f8c9-7a70-bfe3-c90bad583bb7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019ddb46-f8c9-7d92-b7fe-3a577b82b9bd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019ddb46-f8c9-7553-9fbb-d52303a546a6_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019ddb46-f8c9-7bb6-aa4b-e157119b3102_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019ddb46-f8c9-7928-9ec5-ff20ba1843c2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019ddb46-f8c9-7109-8eca-8945802ab060_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019ddb46-f8c9-79ae-8397-9507e2d1951a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019ddb46-f8c9-79fc-ac38-44df5cdb9a06_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019ddb46-f8c9-719f-a196-a888b38a954a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019ddb46-f8c9-70b3-a77a-6a7631f7d3e2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rcus-20260505_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ddb46-f8c8-790c-809f-ed4e4a8549d1,g:570cf75d-5d9f-4510-900f-7a086033b77e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arcusbio.com/role/Cover" xlink:type="simple" xlink:href="rcus-20260505.xsd#Cover"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019ddb46-f8c9-7081-bb1e-f9c132c2b243" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_DocumentType_019ddb46-f8c9-7081-bb1e-f9c132c2b243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019ddb46-f8c9-7ccb-aab0-807bcd3a249e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_DocumentPeriodEndDate_019ddb46-f8c9-7ccb-aab0-807bcd3a249e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019ddb46-f8c9-7944-93fb-c68f4e65e855" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_EntityRegistrantName_019ddb46-f8c9-7944-93fb-c68f4e65e855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019ddb46-f8c9-7406-8553-c5abf4dd32b6" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019ddb46-f8c9-7406-8553-c5abf4dd32b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019ddb46-f8c9-79f4-b66e-42ad40b62b8e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_EntityFileNumber_019ddb46-f8c9-79f4-b66e-42ad40b62b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019ddb46-f8c9-708c-a03f-ae79262f9b4b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_EntityTaxIdentificationNumber_019ddb46-f8c9-708c-a03f-ae79262f9b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019ddb46-f8c9-7220-97d8-45e5329751ad" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_EntityAddressAddressLine1_019ddb46-f8c9-7220-97d8-45e5329751ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019ddb46-f8c9-7bba-af27-a73aca4f8dbd" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_EntityAddressCityOrTown_019ddb46-f8c9-7bba-af27-a73aca4f8dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019ddb46-f8c9-770a-b829-c162132dd551" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_EntityAddressStateOrProvince_019ddb46-f8c9-770a-b829-c162132dd551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019ddb46-f8c9-724e-8216-07da4fb7dd1e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_EntityAddressPostalZipCode_019ddb46-f8c9-724e-8216-07da4fb7dd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019ddb46-f8c9-790a-b5e0-614e33a78f51" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_CityAreaCode_019ddb46-f8c9-790a-b5e0-614e33a78f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019ddb46-f8c9-7e3f-a8cc-404cefad6025" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_LocalPhoneNumber_019ddb46-f8c9-7e3f-a8cc-404cefad6025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019ddb46-f8c9-7ce8-a85e-7d52f3484543" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_WrittenCommunications_019ddb46-f8c9-7ce8-a85e-7d52f3484543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019ddb46-f8c9-728c-92d6-f0733dc003bc" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_SolicitingMaterial_019ddb46-f8c9-728c-92d6-f0733dc003bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019ddb46-f8c9-7997-90ce-b050384c652f" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_PreCommencementTenderOffer_019ddb46-f8c9-7997-90ce-b050384c652f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019ddb46-f8c9-719c-b7c2-3cb96d67ad77" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019ddb46-f8c9-719c-b7c2-3cb96d67ad77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019ddb46-f8c9-71c4-be8c-d77e8c5f132a" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_Security12bTitle_019ddb46-f8c9-71c4-be8c-d77e8c5f132a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019ddb46-f8c9-7802-b494-d163aae820b3" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_TradingSymbol_019ddb46-f8c9-7802-b494-d163aae820b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019ddb46-f8c9-78b3-922b-afc77a8ecb24" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_SecurityExchangeName_019ddb46-f8c9-78b3-922b-afc77a8ecb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019ddb46-f8c9-7d7f-80eb-7e44e72caa3e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_EntityEmergingGrowthCompany_019ddb46-f8c9-7d7f-80eb-7e44e72caa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019ddb46-f8c9-74cb-be5b-8319a9f6bde6" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_AmendmentFlag_019ddb46-f8c9-74cb-be5b-8319a9f6bde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019ddb46-f8c9-73b2-aa16-0b678a221f4e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ddb46-f8c9-7335-8fcb-a8a1604c4a88" xlink:to="loc_dei_EntityCentralIndexKey_019ddb46-f8c9-73b2-aa16-0b678a221f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img230044022_0a.jpg
<TEXT>
begin 644 img230044022_0a.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %Z!#L# 2(  A$! Q$!_\0
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MKR#FCFCFCFO:,0YHYHYHYH _17_@E)\5MT7BSX<W<W*D:UIZL>QVQ3J/_()
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M%O,+<VV<#./XTR<!UXY .#Q7KE?,5*<J<G":LT="=]4%%%%9C"BBB@ HHHH
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MRC)QG&#V)KOZ_GL\/>)-5\(ZQ;:MHFHW6DZG;-OAN[.5HI8SZAE.:^T? _\
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MRJG_ '5%>W45\E7S#$XA^]*R[+0ZE",>A7L=/M=+MUM[.VAM+=?NQ01A%'T
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MO3AS:LT_#_A_3?">B66CZ-8P:;I=E$(;>TMD"1Q(.@ %:-%%?":O5G8%%%%
M!1110 4444 %%%% !7YY_M]_L3PO;:C\4/ &GB*6,-<:[H]LGRNO5KJ)1T(Y
M+J.",MU#9_0RD(# @C(]*Z\+B9X6HJD/^')E%25F?SN<T<U]2?M\?LRI\"OB
M2FM:#:>3X,\1,\UK'&N$L[@<RV_'1>=R=/E)49V$U\M\U^C4:T<1352&S."2
MY79EK2]2N=%U2SU"SD,-W:3)/#(O575@RG\" :_?OP#XNMO'W@?P_P");3'V
M;5[""^C4'.T21J^/J,X_"OY^N:_7G_@FS\0/^$R_9KLM+EE\R[\.WL^FL&/S
M>62)HS],2E1_N5X6>4N:E&JNC_,VHO6Q]5T445\6=84444 8?CG_ )$GQ!_V
M#[C_ -%M7\^_-?T$>.?^1)\0?]@^X_\ 1;5_/OS7UV0_#4^7ZG+6Z!S1S1S1
MS7U1S'V=_P $J?\ DX#Q!_V+<_\ Z4VU?JM7Y4_\$J?^2_\ B#_L6YO_ $IM
MJ_5:O@LX_P!Z?HCMI?"%%%%>(;!1110 4444 %%%% !1110 4444 ?CU_P %
M(E _:LU\@8S961/_ 'X6OF#FOI__ (*1?\G5:_\ ]>-E_P"B%KY@YK]+P7^[
M4_1?D>?/XF>V?L4J&_:G^'0(R/[1)_\ (3U^W%?B3^Q1_P G3?#K_L('_P!%
M/7[;5\OGG\>/I^K.FC\(4445\X;A7Y\?\%6OBM):Z?X3^'5I-L%T6UG4%4X)
M128X%/J"WG$@]T4]J_0>OQG_ ."@GBA_$W[57BY2Q,&FK;:?",YVA($+#_OM
MW_.O;R>DJF*3?V5<QJNT3YSYHYHYHYK[TXCU7]EWX/CXY?'#PSX5G#?V7+,;
MG460D$6L0WR#(Z%@ @/8N*_<BSLX-/M(+6UACMK:!%BBAA4*D:*,*J@<
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M'IN!\QNGWU!'R"OK&FHBQJJ(H55& JC  IU?F5>M+$5)59;L]&*Y59!1116
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M4 %%%% !1110 4444 %?D5_P4V_Y.>G_ .P1:?\ L]?KK7Y%?\%-O^3GI_\
ML$6G_L]>]DO^]?)_H8UOA/E#FCFCFCFONCB.A^'?_)0/#/\ V%+7_P!'+7]
M=?S^?#O_ )*!X9_["EK_ .CEK^@.OD,]^*G\_P!#JH[,****^6.D**** "BB
MB@ HHHH ***\J_:0^/\ HG[.OPVO?$6I/'<:E(K0Z5IA;#WEQCY5]0BYW.W8
M>I*@W3A*I)0@KMB;MJSX%_X*E?$Z+Q-\7M$\'VDOF0>&K(O<A3PMS<;7*GUQ
M&D)_X$17Q5S6GXH\2ZEXR\2:GKVKW+7FJ:E<R7=S.W!>1V+,<=AD]!P.E9G-
M?IF&HK#T8TET."3YG<.:.:.:OZ!H-_XHUS3]'TJU>]U._N([6VMH_O2RNP55
M'U)%=%[:LD_0W_@D[\.Y(=-\;>.;B+"7$D6CVCD8R$'FS?AEH?\ ODU^A%>?
M_ ;X46GP1^$OAOP;:LDKZ=; 7-P@XGN&)>:09YP79L9Z# [5Z!7YKC*_UBO*
MHMNGH=\(\L;!7Y,_\%./B8WB[X]P>&H9=]CX7L4@* Y'VF8"65A_P$PJ?=#7
MZQ33);PR2RN(XXU+,S'   R2:_ ?XI>,I?B)\2?%'B>5F9M6U*XO!N_A5Y&9
M5^@4@?A7K9)2YJTJC^ROS_IF=9Z6.7YHYHYHYK[4XPYK]*?^"4?PS6Q\*^+O
M'MS$//O[A=)M'8<B*,"24CV9WC'UBK\UN:_;_P#8]\%#P#^S3X TPQ^7-+IJ
M7\P/7S+@F<@^X\S'X8KP<YJ^SPW(OM/_ ()O25Y7/9:***^%.P**** "BBB@
M HHHH **** "BBB@ HHHH *\Y_:$^$=I\<OA#XB\'W&Q)[R O93OT@ND^:%\
M]AO !QU4L.]>C45<).G)3CN@W/YY-4TVZT74KO3[Z![6^M)G@G@E&&CD1BK*
M1V(((_"NW\ ?L_?$CXH[&\+^"]8U6!\8NEMC';\]/WSX0?BU?M+:_ /X<V?B
MW4/%">"]&D\07\QN+C4)[1996D.,N"^=A.,G;C)R>YKOE4*H & . !7U-3/=
M/W<-?,YE1[LYOX;#75^'OAM/%$"VWB--/@348EE64"X" 2$,O!RP)X]:Z6BB
MOE).[;.D****0&'XY_Y$GQ!_V#[C_P!%M7\^_-?T$>.?^1)\0?\ 8/N/_1;5
M_/OS7UV0_#4^7ZG+6Z!S1S1S1S7U1S'V=_P2I_Y+_P"(/^Q;F_\ 2FVK]5J_
M*G_@E3_R7_Q!_P!BW-_Z4VU?JM7P6<?[T_1';2^$****\0V"BBB@ HHHH **
M** "BBB@ HHHH _'K_@I%_R=5K__ %XV7_HA:^8.:^G_ /@I%_R=5K__ %XV
M7_HA:^8.:_2\%_NU/T7Y'!/XF>W?L4?\G3?#K_L('_T4]?MM7XD_L4?\G3?#
MK_L('_T4]?MM7R^>?QX^GZLZ*/PA1117SAN%?!'_  56^$\FJ^%?#/Q#LH2[
MZ5(=,U!E&2()#NA<GLJR;E^LPK[WK \>>"=*^)'@W6?#&MP?:-*U6V>UN$&-
MP5APRDCAE.&![$ UUX6N\-6C5[?D3*/,K'\_7-'-=O\ &CX1ZU\#_B1J_A#7
M8S]ILI,PW(4JEU >8YD_V6'OP05/(-<1S7Z7&2G%2B[IGG[!S5_0=?U+PKK5
MGJ^CWUQIFJ6<@EM[NUD*21..A5ATJAS1S3:OHP/TD_9S_P""G6GZA;VNB?%F
M V%\N$'B.QAS#+V!FA490^K("#_=45]T^%_%VB>-M'AU7P_JUGK6FS#*75C.
MLT9]LJ3S[=17\^7-='X'^)'BGX:ZJ-2\*Z_J&@7G&Z2QN&C#@=G4'#CV8$5\
M]B<FI5'S47ROMT_X!O&JUN?T T5^6OPO_P""IGCOPXL-KXTT2P\6VRX#7=N?
ML5W]3M!C;Z!%^M?5WPY_X*)_!OQX(XKS6+CPE?-_RPUR QIG_KJA9 /=F7Z5
M\Y6RW%4=XW7EK_P3=5(L^G**SM#\1:5XGL$OM&U.SU:R?[MS8W"31M]&4D&M
M&O-VT9H%%%%( HHHH **** /CK]K[]A*Z_:&^)&C>*?#NJZ?H%Q);FUUF6[1
MV,H3'DR(JCYWVDJ=S+PB>E1?#G_@EY\,_"YCG\4:AJGC*Z4@M&[_ &.V./\
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M/_HIZ_;:OQ)_8H_Y.F^'7_80/_HIZ_;:OE\\_CQ]/U9T4?A"BBBOG#<****
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M&7FOLS_@J!\5_P#A+OC-I_@ZTFWV'A>TQ,JG@W<X5WZ=<1B$>QWBOC/FOO\
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M[J*X26&$JZ,CA@RX7J".*VCQO.I[KRZJK_X?\T92R>G%76)@_O/J>BBBLCS
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M"_[!OP.\*LKQ>!X-2F4Y\S5+F:YS]4=]G_CM>T^&_"&A>#K,6F@Z+I^B6O\
MSQT^UC@3\D %>;4SRFOX<&_73_,T5%]6?E!\'_\ @F_\4OB)-#<^(8(O NCL
M06EU/Y[IE_V+=3D'V<I7Z$? /]D'X>?L^11W.BZ<=3\0[-LFNZEB2YY'(CXV
MQ+UX4 D<$FO;J*\'$YCB,5[LG9=D;1IJ(4445YAH%%%% 'RK_P %+93'^RWJ
M*CH^IV:G_OLG^E?D+S7[ _\ !2:U-Q^ROK3@9$.H64A_[_!?_9J_'[FON<E_
MW9^K_0XZWQ!S1S1S1S7OF!Z=^R_C_AH[X8YZ?\)'8=?^NZ5^ZU?@G\"]0_LG
MXV?#^]+;1;^(+"4GV%Q&3^E?O97QV>K]Y!^1UT=F%%%%?,'0%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'XY_Y$GQ!_V#[C_P!%
MM7\^_-?T$>.?^1)\0?\ 8/N/_1;5_/OS7UV0_#4^7ZG+6Z!S1S1S1S7U1S'V
M=_P2I_Y+_P"(/^Q;F_\ 2FVK]5J_*G_@E3_R7_Q!_P!BW-_Z4VU?JM7P6<?[
MT_1';2^$****\0V"BBB@ HHHH **** "BBB@ HHHH _'K_@I%_R=5K__ %XV
M7_HA:^8.:^G_ /@I%_R=5K__ %XV7_HA:^8.:_2\%_NU/T7Y'!/XF>W?L4?\
MG3?#K_L('_T4]?MM7XD_L4?\G3?#K_L('_T4]?MM7R^>?QX^GZLZ*/PA1117
MSAN%%%% !1110!'-#'=0R0RQK+%(I1XW *LI&""#U&*^5/C=_P $Y?AK\4'N
M-0\/(W@37),MYFFQAK-V/=K<D ?]LRGXU]7T5O1KU</+FI2LQ-*6Y^-?Q:_8
M!^+GPM:>>#11XNTF,%A>Z!F9@HY^:' D!QUPI''6OG2[LY["YEM[J&2VN(VV
MO%,A5T/H0>0:_H?KB_B!\%_ OQ4M_+\6>%-+UTXP)KJW7SEXQ\LHPZ_@17T-
M'/)K2M&_FC!T5T/P/YHYK]4/B'_P2S^'?B 2S>%-:U;PG<MG;#(1>VR^@VN1
M)_Y$-?,/Q$_X)H_%SP>)9]%CTWQA:+R/[.N/*GQ[QR[>?96:O;HYGA:VBE9^
M>G_ ,73DCY-YHYKH/&'P]\3_  _O?LGB;P]J>@7&<"/4+1X=W^[N R/<5S_-
M>HI*2NC,.:.:.:.:8@YHYHYHYH V/"GC+7? NL1:KX=UB^T34HC\MU83M$_T
M)4C(]0>#7VS\"?\ @J)KFAM;:7\3],&O6/"?VUIJ+%=H.!F2+A)/^ [#]:^#
MN:.:Y*^%HXE6JQO^9<9..Q^_'PW^*GA3XO>'8M<\(ZW:ZUI[X#- V'B8\[9$
M.&C;_98 UUE?@/\ #+XK>*O@]XG@U_PEK$^DZA&0&\MLQS+G[DJ'Y74^C#WZ
M\U^LW[)7[9VA?M(:;_9=_'#H7CBUCWW&F!SY=RHZRVY/)7U0Y9?4CYJ^.QV5
MSPOOPUC^*]3JA44M&?25%%%>&;!1110 4444 %%%% !1110 4444 %8GC;Q=
M8^ ?!^M^)-3?9I^DV<M[.1U*1H6('N<8 [DBMNOB[_@J'\6/^$3^#^F>"[2;
M9?>)[O=.JGD6D!5V^F9#$/<!QZUTX:B\16C275_\.3)\JN?F)XR\57WCKQ=K
M/B+4W\S4-5O);VX8=-\CEB![ G 'H!6/S1S1S7Z<DHJR//-GP7X3OO'?C#1/
M#FFKOU#5KV&R@&. \CA03[#.3[ U^^?@_P +V/@CPIHWA[3$\O3]*LXK*W4]
M=D:!%S[X'-?EU_P3!^%?_"8?&V^\6W4.^P\+69>-CT^U3AHXQ[X03-[$*:_5
MVOC,[K\U6-%?9_-_\ ZJ,=+A1117S9T!113))$AC:21E2-069F.  .I)H ?5
M+5M8L- TVXU'4[VWTZPMUWS75W*L442^K,Q  ^IKY,_:$_X*/>"OA>USH_@Q
M(_&_B*/*--#)C3[=AQ\TH_UA]H^#TW U^<?QB_:'\??';4OM7B[7Y[RW5MT.
MFPGRK.#_ '(AQG'\1RQ[DU[>%RFMB+2G[L?Q^XQE44=C]"/C?_P4X\%^"S/I
MW@&R;QIJJY7[=(6@L(S['&^7'/W0H/9J^"/C!^U-\3/CA)*GB;Q+<'3'.1I%
MC_H]FH]/+7[^/5RQ]Z\FYILDBQH7=@BCJS' %?68;+Z&&MR1N^[W.:51RW'<
MT<UZ/\-?V>?'7Q46*XTS2O[-TA_^8OJV8("/5%QOD_X",>]?47P]_8M\%>&/
M*N/$3S>,M1&"4NAY-FI]!"IRW/\ ?)^E?+YUQIDV1MTZU7GJ+[$/>?SUM'T;
M3\CV<%DN-QUI4X6CW>B_S?R/A>-'FMFN8XI'M5<1M<*A,0<]%WXV[N#QG/%)
MS7ZC?&;]G/5?'W[/_B?2]-T2/3H;&S.I:=;QPB$&> >8BQQJ!RP!7ISNZU^7
M/I7;PWGLN(,++$SH.E:323UNK)J5[+?7IT.?,<%' 5E2C44]-6N_8.:.:.:.
M:^L/*&R1K-&R-G:P*G!P:_9?]CF[\-_%WX!^%O$,]DEYK$, T[4FGD+G[1
MC,1]T;U"R8QP)!UK\:N:^\_^"5/Q6_LOQAXF^'UY-B#58!JEBK'@3Q8655'J
MT95OI#7S6?9=0QV'4ZU-2=/572=K[VO\ON.W#8BK0DU3DXWWL['Z26>C6&G
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M[#MDQZQBO/Q]#ZQAY06^Z^1I"7+*Y^XM%-5ED565@RL,A@<@BG5^;G>%%%%
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M0*?%KX0Q>&-3N0_B;PJB6D@=OGGL\8@E'K@#RVZ\HI)^<5]85^#?P)^,VL?
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M+7] =?S]?#^01>/?#;M]U=3MB?PE6OZ!:^1S[XJ?S_0ZZ/4****^5.@****
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M444 %%%% !1110 45!>7EOI]K-=7<\=M;0J7DFF<(B*.26)X 'J:^)?VDO\
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M?5G>%%%% !7Y2?\ !4KPG_8_Q\TG6D7$6L:+$S-CK+%(\;?^.>57ZMU\$_\
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M:B_9UTK]I'X:W&A71CM-;M2UQI&I,.;:?&,,1SY;X"L.>QQE5K\4?%?A75?
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M[17XO:+^WU\==#C")XYDNT QMO;&VF/_ 'TT>[]:UYO^"CGQUD3:OB:RB/\
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M@AXJ_P# ^'_XQ1_PZU^#_P#T$/%7_@?#_P#&*/[9POG]P>RD?D[S1S7ZQ?\
M#K7X/_\ 00\5?^!\/_QBC_AUK\'_ /H(>*O_  /A_P#C%']LX7S^X/92/R=Y
MHYK]8O\ AUK\'_\ H(>*O_ ^'_XQ1_PZU^#_ /T$/%7_ ('P_P#QBC^V<+Y_
M<'LI'Y.\T<U^L7_#K7X/_P#00\5?^!\/_P 8H_X=:_!__H(>*O\ P/A_^,4?
MVSA?/[@]E(_)WFOWU^#W_)(_!'_8#L?_ $G2OFS_ (=:_!\_\Q'Q5_X'P?\
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M_!__ *"'BK_P/A_^,4?VSA?/[@]E(_)WFCFOUB_X=:_!_P#Z"'BK_P #X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"&V?@G_P!#Y:_^ ES_ /&J /<**\T^'W[2'PW^*GB Z)X5\40:OJGDM/\
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M*** "BBB@ HHK!\;^.-#^''AF[\0>)-032]'M2@FNI$9@F]PB\*">68#@=Z
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M *635\+_ /!0[_DYK5_^O"S_ /10K[H_87_Y-7\#_P"Y=_\ I9-3 ]YHHHI
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MT^\U:WMKBVN$#I+&[A64@^H)K:_:8^!>H?L\_%2ZTA3,VD3M]LT>_)P9("W
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M^A^T_P#[]S?_ !% 'M%%<SX ^)'AGXI:(^L>%=7AUK38YVMFN( P D4*2IW
M'.&4_C734 %%%% !7(?&+_DD?C?_ + =]_Z3O77UR'QB_P"21^-_^P'??^D[
MT ?D+^S'_P G$?#G_L.VG_HU:_4G]J+X!V?[07PQNM'VQPZ_9[KK2+QQCRYP
M/N,>R./E;TX;!*BORV_9C_Y.(^'/_8=M/_1JU^U--@?B;\*?B/XC_9S^+5OK
M,$$MMJ6EW#VFHZ9,2GFQAMLUO(.QX[@[653C(K]E/ OC;2/B/X1TKQ+H5R+O
M2M2@$\$G&1V*L.S*P*D=BI':OB7_ (*+?LW>:A^*OAZU^=0D.O6\0ZC[L=UC
MVX1_;8<<,:\\_P""?_[27_"M_%__  @>OW6SPUKLX^R32GY;.\/ Y[))PI]&
M"'@;C0!^G=%%%(#\\O\ @J?_ ,C%\/?^O6\_]#BKO/\ @EW_ ,DK\7?]AD?^
MB$K@_P#@J?\ \C%\/?\ KUO/_0XJ[S_@EW_R2OQ=_P!AD?\ HA*?0#[1HHHI
M %%%% '._$3QI:_#KP'K_B>]&ZVTFRENV3."Y1250>['"CW-?BC#'KGQ@^)$
M:-)]M\1>)-3"EVX#SSR=3Z#<WX"OTU_X*)>(I-#_ &:[^UC8I_:VHVMDV#U4
M,9B/_(-?&W_!/?PM%XD_:5TFXF02)I%E<ZAM/3<%$2G\&E!^H%,#]/?AI\/]
M+^%?@/1?"FCQ[+#3+=85;&&E;J\C?[3L68^[&NGHHI %%%% !1110 4444 %
M%%% !7S]^WI_R:OXR_WK+_TLAKZ!KY^_;T_Y-7\9?[UE_P"ED- 'Q)_P3K_Y
M.5T__L&W?_H K]7*_(3]B/Q]X>^&OQWM-;\3:I#H^EQV%S&US,&*[F4!1\H)
MYK]$_P#ALKX+_P#0_:?_ -^YO_B*; ]HHKQ?_ALKX+_]#]I__?N;_P"(H_X;
M*^"__0_:?_W[F_\ B*0'M%%>+_\ #97P7_Z'[3_^_<W_ ,17J_A_Q!IWBO0[
M'6=)NDO=,OH5GMKB,$+)&PR&&1GD4 :-%%% !1110!^:_P#P5"T&:V^*WA/6
M2K"VO-&-JC=B\4SLP_*9/SKU_P#X)F^/M/U3X4ZSX3,R)J^DZ@]UY!.&>WE5
M=K@=\.K@XZ97/WA7L?[5?P!A_:#^%\^D0M';^(+%_M>E7,G"B8#!C<]0CKE3
MZ':V#MP?RET76O&O[/?Q(^T6QN_#/BG293'+#,F#[HZGAT8?4$$$=C3 _<"B
MOBOX2_\ !2_POK=O;V?C_2KCP[J& LFH:>AN+-S_ 'BG^L3Z /TZU]6^"?B=
MX3^)%G]J\+^(M.UR+&YA9W"NZ?[Z9W+^(%(#IZ*** "BBB@ HHHH *\Z_:#^
M+EI\#OA#XC\87)C:>RMRME!)TGNG^6%,=2"Y!..BACVKT6ORB_X*0?M&Q_$[
MX@P^!="NA-X<\,RM]IDC;*7-_@JY]Q$"8P?[S2=00:]' 85XJNH=%J_0B<N5
M7/D#4M2NM8U&[O[V=[J]NI7GGGD.6DD8EF8GN2235?FCFCFOT<X YI.G)-+S
M45TC2V\J)P[(0#[XIK<1^CW[,6A_V!\ O!L)39+=6K7\@_VIG9_Y$5ZA7+_"
MO4K35_A;X.O+$ 6<ND6IC5>@ C52/P((_"NHK^!\WK3Q&98FK45I2J3;79N3
MT^1_06!A&GA:4([**_(*]!^"-KY_C"24CB"V=L^Y*K_(FO/J]7^ =ONO-8GQ
M]V.-,_4L?_9:[^&Z?M<VH1\[_<F_T./.9^SP%5^5OO:1[)1117]('XX%%%%
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M_10K[H_87_Y-7\#_ .Y=_P#I9-7PO_P4._Y.:U?_ *\+/_T4*^Z/V%_^35_
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M.^#KSX>_"OPIX9U"6">^TG38;.:2V),;.B $J2 2..X%=C10 4444@"BBB@
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MA[2*._\ $HW#^(+[_P#L?_MV6NCZ;9>"/B5>F*WMU6'3O$,N6"H.%BN#U '
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M_P#);/A__P!C#I__ *4QU^T/C[_D1/$?_8-N?_135^+OP-_Y+7\/O^QAT_\
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M,?\ P3S&@WUGXF^**6]W<Q$2V_AN-A)$C#D&X8?*^/\ GFN5]2PRM?=( 48
MP*6BI **** "BBB@#\GO^"AW/[36K\?\N%G_ .BA7W/^PO\ \FK^!^WR7?\
MZ635[K):PR-N>*-V]64$T](UC4*BA%'0*,"F ZBBBD 4444 8'C[_D1?$?\
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,%4 "KU( HHHI ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  05,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arcus Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3898435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3928 Point Eden Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hayward<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">694-6200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCUS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001724521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rcus-20260505.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="rcus-20260505.htm">rcus-20260505.htm</File>
    <File>rcus-20260505.xsd</File>
    <File>rcus-20260505_lab.xml</File>
    <File>rcus-20260505_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rcus-20260505.htm": {
   "nsprefix": "rcus",
   "nsuri": "http://arcusbio.com/20260505",
   "dts": {
    "inline": {
     "local": [
      "rcus-20260505.htm"
     ]
    },
    "schema": {
     "local": [
      "rcus-20260505.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rcus-20260505_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rcus-20260505_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2026": 24
   },
   "report": {
    "R1": {
     "role": "http://arcusbio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260505.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260505.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001724521-26-000032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001724521-26-000032-xbrl.zip
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MD$Q^_*%[>$SSBF*5/Q\F--"! CH%L.PK_"[!87T<"^9B8KJ(/N0ER)2><65
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M7D2Q]\35YY/+>JOMR@9*>IA?)NCY;@YOI,:Y\+>8$P$V .#I/[/\OLIEE-Z
M4=]* 4P)A$*P=4B*<A%,D)%.2)E<.Q^N3M]A&0P[_FUX(,:D(1B)4\(*+?4"
MJ"521#)LY+\W(4IA7-PIW*'3%"PJ-B<HPP! +%8W&HX*-JE0>=#GB)%C=A<,
MLE1SJASLS231"9@P',Z?^8;C<.5]M!&+<H#>USYZ884>8WZ>$A^OA(L*B-3F
M>E1]DO?L<",_4Y J@2F[>OC0V^+\[-?S^CO<6%NDX>RX@EA>IMMQO[E.;D<
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M]QE6"7E(J4G>ZZK2JD+#]H. QEJ\RIX\;E."*2F!35+@((#$ZA;\!O3?\3>
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MD,.7^0FTODSEF;N<Z=%*)#AL[O(]SATEPKZ^:YX<V5/3&BB%,[/DZH46VH)
MSGX4.K=%<DD%^1?U8T;^KN*$)KD$JZ8_?-$:W>]G(U*=E6B!V2XT"JVK]J?^
M#P)_/4[/;/#DHL[#VA+4(\ME)683#A2P4A'6?X?B-I&'F2G_?/%"SL3S]FG7
M#5ST7A@93(FC$B@ T2VH3Z;J=!]D-[@D !VX/@CT#;D1X7TT1"=HC!D/*HG+
M/%A"7?Q)HK!&=<55P_D-PS(YPAMQ]1-,<I>;)RH@FXV!U8"^8[PYA)FXQ*&R
M!IJ5\_;BP[G1SIP/7YA=WR ?L^7]Z:RA]89YXJV'$9+2GPSZ=PKX=@+[LQ$$
MRW@J@K!O.]3UGI")(DC"2@'CCS*'0Q ?YH-O#.(3A,I3CB53O8#&:7X2WPKB
MRGM.WA-!4JJU_"DNKIYR0O8( "UH$>R.2Q@'0DD#!V/,U''P+@YVQF=]7"I<
MF60FW75N>OF(SMST13'3=\2$X08IZ+W*GA[N4R2+#\B,PX0#;<%\BH5K:Y^4
M2=<VYD/H (R+.%H_9,-7:#9](:<^>R%G*.9&T@W3!H+16XUZ<!K8U+^G4XE$
MV=4S.B]=/[&FN#]B(V+IAD6NF(S]2!4J7H">28.;H"W(VYDB:8>@V+!!_X*B
MES]C&7%OFGP"#0FVI%W>B?:^"+;^#D#Y^8< BF3-G7&PP&0,BIJ"SL924I!!
M1N&4H$$ :MU1]2RP<7-]+]*MQ',"%7@T%(P1!2 <-^I0^4B%,TS *9L)/#I!
M:]>+?9^HU[E2[;^\)AA07BP"+H<($)I@0S[@$6DV=9. \<C@$$&>404VV84I
MZ(I-8!_">3A['.RP>0AIQ8/9$WYH_"KS<BY0F<$YJSTZXK/*S46R'3^L1AJP
M11H#,>60PJ:@?0!-+@.SPR5HWUJ &_>9J_XV3]1^PVD.FI<I.9Z=YHV<QG,1
MMY2.$DB.<$"ZS&+G=+7C(AH;(7H,]V!O$!D/_H3U$ $<Z',ZX'ZRE%J<@I.9
MP%,$5$2*%%_$:8EC%ED%J8L63EJ,M;;$(_4OEM ('V=@BA@U8F/U;@&;* ;'
MJB\6(07!F(*E9?*<@;,,@XR=80K$"N[-^6";L>K%-O1!-6!J09W(EO$(1&!Z
MLA^G0U,WS(4S0-W20(68' XI)\O<TIQ:(1J&().7EA:%6<,OVY?F(W<WQ;_+
MU*CIY0IBOQ%-#\KHU8WJI@FGETY$-1JZ62GO(A'UM3@MWVMEV9'3"_6O%T4\
M#-3?,.D(/EZZ=_Y2R8"MH)U3JZ%UL>.(\7.)IK4T\;P7T;<*-)<YZ3U^6YD2
MV O H2L/8Y;(S<DN82/)@[L4S?2_S,9M"E.S:>K#:*1*5!9L=%?93Z<E>L@H
M@;=$9HX2776-<\^U<DX9-8W*MZ..\U[:" $0<DG!&N]B0@EX$N]"@F--DU<E
MCMAHP%PW?:=>N5;8%6<B2^_9;U(V]:W$L[#0_U "6OM0+M#OONN=7W^ZRO=Z
M\=X&'!8?]TRR"'_%7*2>6%[W?D7ZP8W!]W5HC"D#%:](7LM, Q$2B(!.=*!"
M3 ,&3KN'_C%.I)1YV@'# "P.8)":C\;1,!2 G;N_/LP75OC5],:&/LRZJ2R]
MV:Q_G6(Z!.JK7*!:><#4]K1>=[6\GV/A!'G=O>BWNYU>N],ODFZOK:^R_!\<
M#;M\K>:%7@C;NIK"Z/CVG]FM;/K.[H'7I+^>VAM8C?M=R5.2)7+-A)C"/)(%
M17(YU,F;E?*Z'=E<Z^@>3G740WKNDIR']:);[GOGG'F/WG'9EZ?=\D:]U[](
M\_#=YH/WKTK)O_VD_L&HUO\ 4$L#!!0    ( "B!I5Q8$I?<7@(  .T&   1
M    <F-U<RTR,#(V,#4P-2YX<V3-5%UOVC 4?>=7>'F>$P=((:A0::TJ36(?
MZEJM;Y-CWX#5Q,YLI]!_/]LDHI2V$WM:GNQ[S[E?/C?G%]NZ0H^@C5!R'J4Q
MB1!(IKB0JWET=WN-I]'%8C X_X#Q_:>;);I2K*U!6G2I@5K@:"/L&MDUH)]*
M/XA'BKY7U)9*UQ@O NU2-4]:K-86#<GPK(?U7CTC:<YY,3[#Y91-\20G#$])
M7F+@8QC3:3;.>?IQ-<LFA)63C..,.^<X2PG."2GQA)+I&1F-BLD$0M"MF1FV
MAIHBUYHTLZV91VMKFUF2;#:;>#.*E5XE0T+2Y/[+\D> 1AVV$O+A +TM=-7C
M1XEW%]1 #]>LW0>G_E8(%3-5)[Y5DI$L0M1:+8K6PK6;R164M*WL/&KE[Y96
MHA3 W< K\",] #QS6ZI78+_2&DQ#&?PEX6* D)^!J!NE+9)'M..VA#262N;:
MV@UNJ1BU00]O4OP-]SSL33@=XE$:;PV/DG^H83_:TVKH>:?7$((98/%*/28<
M1!CAZ^G-6W!_P/YPF)-*J6S@>TMG:QHA2[4S.),O?-97?P-EK]8C"7:"3?,\
M3X+7J2^0W?MK5<'[X*31J@%M!9CG\@T!UAK*>>15A'OY_&HTQ*Z2'G*4X/ )
MO-ME ./D&_I=[AOJ0]BGQH4P[ATJV(WH?^Z_HL6I_3L*5"<V[HFWSH\$GT>7
MROV (^1M=S>?7]_OD&D'["/UL3B40HJ@-A*^%.']?QJCP#I/7F)?1&D-\&]R
M$<XO7[0C=Y!WB(Q6K*U.Y^W+>I/6&?O!=8N5'&[6[OYL^X)AM]*+P1]02P,$
M%     @ *(&E7+XL^R0^"0  ?54  !4   !R8W5S+3(P,C8P-3 U7VQA8BYX
M;6S-G%UOVS@6AN_S*[B>FUU@&.M;8M!FT,VTBV S;="DF,$.%@$I4HDPLA30
M2I/\^R5E.Y$LRB:I6-V;QK&9\Y[WV(]%'E)]]\O3H@#?&5_F5?E^YAX[,\#*
MM*)Y>?M^]NWZ$TQFOYP>';W[&X1__//K!?BU2A\6K*S!&6>X9A0\YO4=J.\8
M^+WB?^7?,;@L<)U5? 'A:?-G9]7],\]O[VK@.5ZT&;9YE9\X+J*4!!',DC2!
M,7)2F#@H@XP&+,!)&"#J_GQ[$L9.FL4AA2$5+P:AZT#D.!F,L9-$CN^3.&9-
MT"(O_SJ1_Q"\9$#8*Y?-K^]G=W5]?S*?/SX^'C\17AQ7_';N.8X_WXR>K8<_
M]<8_^LUH%R$T;UY]&;K,50-%6'?^QV\75^D=6V"8E\L:EZD46.8GR^;)BRK%
M=5/UO7F!P1'R-[@9!N53T/6@[QX_+>GL] B 53EX5;"O+ /RY[>OYX.2:"Y'
MS$MV*]_;2\;SBE[5F-<7F+!"9-]$JY_OV?O9,E_<%VSSW!UGF3ILP7DGJLP2
MR2S=2&;YTY#8?$3Z;Y1OW<_U#9)K['Y^JQQWU?3SFZ5[+;XAV.$3;LF,3GGU
M@?I8TJD^NR]2HU,_?,9O];&H:EQ,\+%XE6FE7,@G+L2CM8P,M./+M-%9?W6W
M4F5/-2LI6WU;=D*#G+Z?B4<WE.4W'\LZKY^O\=,Y%5>_/,M77]Z?'Q:$\9OV
M-0S!V(D=2)+0@4&<.>+BE.$D\6[JEP_W#2OAMZM-'HV8IM+,P&L]P"QGR^J!
MIZNKG5"75_I50J<K;2#$05<=K.3?S5\S'E.O8KHJ%-,4H$H[$H6\N%=\VUR5
MZIM[I68IW#7.EBP]OJV^ST6,N9Q,R0=0/FA@V1]YWGO//O!-WIBG>\JY'C%/
M*S&3N:]AI[(9KQ:&!NO*\.U>E5:D,0,5IXR+^:K"DN)C^"DOF)K4,"(0HU1,
M*".4A"E%./4C,U)?@T\#I]2SQ+%5!UT"[=Q90:=CS *SOH,19+6"30Q3WT:?
M'\48<V3.*K$<_$"6-<=IO<T+BR)(Q*(,>B%+$Y:0)&*.+B^=R >&I=$"?V[4
M_JN/2M?_?DZL79E!HFW("!%E\E9\="--!H?20)L,]0!S+*Y8^L %8ZY'KO.Z
M8+TK21) $H8QQ!YUW#2B21R&NF1L!S\P'(T&J#+@>G\G_P ;=7U&>L78C\D8
MBV:DF+HS F;(AA4SO6"383-DHTW.X!AS>&2OJ[B\J\J!:1AQ&22$Q9 &R MC
M1 E!3!>>[> 'AJ>1 XV>\32L5X?]W(QQ9\:-@3$C9(8<6"'3"S89,D,VVL@,
MCC%'9M-H?^DM_8KKWD6'9*FXZ#@AS! .@AAEE$:)+C=*A0/#\[)]L!(%0A5(
M67V$U'79S]%HMV8P&1LU0FJG&2NNU!$G@VNGH39ANP=:3.NJ(D_S.B]O?Q.!
M>(Z+;<;\$$%"(Q\Z;A80%[DA=K'VQ*X7_L" O0J"C:+!M*Y?#(V)W2B+9E29
MN#.;U@V:L)O8]<---[4;M-*9W V/LNVR?:!4O'7+]8^+O&3N-DL>C2"2.[Q9
MD(4L)3'V7>WKU:#*-'VWM>+/FP= :H,OI<&U:[A.NNVXD>ZM^G+FQBVZ=#N,
MC6C7J:).W+?;8:S?P-LU>"26E]6RQL5_\ONSBO;FD32+88(\!ED0A2R,?2=R
MD167'9F)P5QI R$.I+HEE]U"&8)I;7\<F;K.[<%4&AM/9C?LCT%3:6V03?5H
M6SB_LMM<MB;+^C->]+",W0 21%/!9D9#YA+B!]I33Y7 -$"^:@(I:LKA5DUT
M";1W:L6>KDD+Y-1.1L"V%7!BS-1V^H -C#-'ZX-8(%*Y2/Q4X-MMI@*60I*&
MGNS3>Q%E"66(ZC+5B7Q@F%ZT@!33AZCK?C\]UI[,L-&T8X2+,G4K3KJ1)@-$
M::!-AGJ .1*7G)U5"Q$H93+:^7+YP/BU//C$OV19OR$?D!#B$".8Q%Z2Q2B(
M(OV%VCZQ X,CY&':T@>K!, J ]"DH(_3WLKM)^PMZV$&W:A2&*&HZ]&*SKW!
M)P-6UV:;8>V_&;G"NZIQS;[P2UY]SX76-M(8,8A8B&"$G"R. R\+0L-#B6JA
MB5=YC;JH$-CH6Z[SMLMEN-(;481Q:SU]__:KO0%SX]=[VX%_S(IOP-[@FF]H
M_$A@S\3#+_RZ>BQ[K,H#Q!GS88H<@FF8^(3$5JR^:DR,J126GU(I;4EHJSZ&
M<-JY'L>EEF%[)/N6QM/8BOEC0.R;&F10,=06O_,RK?A]Q9LCQ@W;9]5#6?-G
M96L4>9#$&8,^#N.8)!Y!1'N]J*$W#9:=%%K7D'4B5OW2W674)?;-BF-%[ZBZ
M6,"LY78$V+OC3PRYEMD^\'I_9@[_[SRO:U;*N?A#N;[!8-D[QAGZ$&6$0!IZ
MOB.8#R*L?4. 4N' @*\U05=4GV5U5?;3.]JK&:^&-HW0W&G%"D9UQ,GPVVFH
M#=SN@?:'I#\^I7?BW6.J30U"(HAQ0"!SP]AU$?%=1WL=JA(X,& ;2;#1--S4
M4-9D/U]CG9KA96C2ZLBTRLFH8].=@),?G5;941V?5HXS1^N:8_F?,EP]+TC5
M.Z.&O 0BEH8PRSRQ8'23P$^UF>I$/C!,:RVP$M.'J.M^/SW6GLRPT;1CA(LR
M=2M.NI$F T1IH$V&>H#]$>EK\:?;1+@.@@E+,4Q0$":.AXD3:=^HU@Y\8"!>
MS@E++?-3T(WU_3C8&C*C0<^+U4'G=N*CSC<W@28_UMQ.7W6:N?.ZQ2V;LDW"
M&5;U+Q!F,/%1#%'HQ,RC+@KUCR^W Q\8A*9])K4,>Q$=[_M)L'5D1H*F&;-;
M-169V]VIV0XTW8V:BO0[]VFJ7A^]T;UCBQME*<2IG\ @H%F84H*PH[W2'Y:9
M>G/[37:U1^UG_YB=[(-O81]H\_K_8=O:;,/Z+;>JST0\CHMS$?'IW^RY-VM#
M&<0NBB!.DH3X"4:AZ8''+85IVNMK4="H B%KVDO?KHMN]WR$6ZM^N;Y1B^;X
M@)D1[?#MB!,WP <,]5O>0P-M,?NX8/Q6++'^Q:O'^D[ ?(_+'FP.\2&.8PPC
M'$>^F\749X8'0I0ZTR"WD08K;; 6-P5/72E=_$;[MX+0U+H%BCN-C0!2'7=B
M+'>:Z\.Y>_@0HNUWXT(\.CW:/).O_K?.TZ/_ 5!+ P04    "  H@:5<<V!E
M\=\%  #6,   %0   ')C=7,M,C R-C U,#5?<')E+GAM;-6:6W.;.!3'W_,I
M6._K*A9"@,@TZ63==">S:9-)TFEG7SJZ'-E,,?((G#C??@6)V\0X7=8P8_KB
M"TB<<_[GARX'WKQ=S3/O#FR1FOQXY!_BD0>Y-"K-I\>C3[?O$1N]/3DX>/,;
M0E_^O+[PWAFYG$->>A,+O 3EW:?ES"MGX'TV]EMZQ[VKC)?:V#E")W6WB5D\
MV'0Z*SV"2;1NMCYKC["?*"5HA#23#,4)EHCA1"-0%"AG(4V4_\?T*(RQU'&H
M4*C<21KZ&"48:Q1SS"(<!"*.H;YHEN;?CJH/P0OP7'AY4?\]'LW*<G$T'M_?
MWQ^NA,T.C9V."<;!>-UZ]-1\U6A_']2M_21)QO79[TV+=%M#=UE__.7#Q8V<
MP9RC-"]*GLO*0)$>%?7!"R-Y6:O^GWYYK[:H_J%U,U0=0CY!@7^X*M3HY,#S
M'N6P)H-KT%[U_>GZ_+M);N6R$*DYE&8^KDZ.)\;!X-RLNY4/"S@>%>E\D<'Z
MV,R"/AY5_5"53QSBL#+V^V/'\0^;"PN% Z6.\<(=>.I?6?E_]F%50J[@,9[U
MU3,C7S3**C7-]YX9%Y#51[\J2+_65ST516FY++\^)RY!<1"$B&DI$&?<CS"5
MCCKV,MS*W<+Y6XM?@#R<FKNQN_"XDJ#Z46M1Z] P]ZC);GZO[[9;UW;3;<Q\
M)(0/2"?2#X@D@M"@D]O/K;WT^GDN3ZWTC%5@W7"Q-N?R^"*O35"?6HP7W+H+
M(3E+,[7NK:V9]Y&KTO2@W&-:G+LCST6MP5I0%X]9>36X.K+2#:)0M^PCXU=@
M4Z/.<O7.C;*; <A* "ZP&RAC(57 "4V@E]2_,-N* 3)\!G;7<L\PG.5E6CY<
MPS2ME,C+CWS>\#^A%"6!%DA&3%.(0F!AV(F%;59;H1 ,%X7.2@Z"A'.W,K,+
M8VOA;YS^,#'+O+0/$Z,:X5 <(1= @&3(A:9*!41$/8#Q4R=:<4*'SDE_.@\"
MF_=I!A^7<P&V@;RF2$01($JXHEA$1+!N$\FFQ59 A$,'8D<%!Y']6[XZ5TZK
M5*>/&X[M@6 F$<>!1ASBA$1$)X**'E!XQ7PK+J*A<]&'MH. Y%0IEX+BZ<MM
MU\#?#((0M^..%7-[;P@#DL2ASU4/@&PQW0J.>.AP=-5T2&!,W,]+>VON\\T0
MA."(:Q(C'@=<<JJ9$CUB\<-P*RC8+P+%CGH."8EZ771IKZRY2W/96!;%F"/!
M2(*D'Q&WRU8J#/W^N-BPW@J.Y!>!HXNR0R+DRA0ES_Y)%]N6S80"8L2/$(Z5
MHUS$2OE]+#VWV6Y7S,*_"!Z[R[IG.*I![]0"W^9W4D$= D:13R$(>,QTQ^'B
MN;5V  RXG+FS='M.>?60([N:F?R5[1-4BV(F):(N>-!<19ATJUYM6FR7^@%7
M,3M)N.?T?[9I64(^,?/Y,G_:(A6-"BPP%T (*%8AT0%E-.SX(&.KV78@#+B&
MV5W,/=-P8[)4IF6:3S^X!8Y->=:8O=Q&.2'*_<5.%R6= T)V0J%ILQT' ZY1
M=I1QSQ!<6:@(!K>PK9_/58]V[:766TIK28P2+ $)'.* 41DYHCO!\+KM=E ,
MN$[9DZS#@N.\*)9@?Q*+GT@D8DE0($42J2CF*H[[1*3A03M0!ERX[%7B?4\H
M()=N4GSPB;A-RZRQ,O8E10+<8.A<=E^A=KMEWFTZV;#8#H<!ERH[2;CG]-]:
M7KVG=O,P%Z8Q!S),D* )1<J/ LZ!$2RZK2I?F&N7^ &7(W<7;R W_=E*SG@^
MA6V/\ID(W *(.!6TC&/.0 I">[GQGUMMQ\" JXZ=I1Q$M?%L#G;J4/[+FOMR
MYB:W!<\?-L-0L48,@W#[94HA)I+SH(]RXU;C[5Z<&GR]L;NP>^;CU*UP5+7*
M>9_Q:>.]#:>#@% @%O@)3W0D%'1[/^:%N78,#+CDN+MX@Q@5)LYSR[-SM[!=
M_0T-; -!$.=5G5Q$,>.$^)KV,1YLF&U'P8"KC]W%[(V&-^.&B!?NP,G!TXGJ
MHWH-_N3@7U!+ 0(4 Q0    ( "B!I5S[4: STR(  .04 0 7
M  "  0    !A,C R-G$Q.&ME>&AI8FET.3DQ+FAT;5!+ 0(4 Q0    ( "B!
MI5P655*$] X  #]M   1              "  0@C  !R8W5S+3(P,C8P-3 U
M+FAT;5!+ 0(4 Q0    ( "B!I5Q8$I?<7@(  .T&   1              "
M 2LR  !R8W5S+3(P,C8P-3 U+GAS9%!+ 0(4 Q0    ( "B!I5R^+/LD/@D
M 'U5   5              "  ;@T  !R8W5S+3(P,C8P-3 U7VQA8BYX;6Q0
M2P$"% ,4    "  H@:5<<V!E\=\%  #6,   %0              @ $I/@
K<F-U<RTR,#(V,#4P-5]P<F4N>&UL4$L%!@     %  4 20$  #M$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>rcus-20260505_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rcus-20260505.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2025-10-28</startDate>
            <endDate>2025-10-28</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001724521</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-05-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Arcus Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38419</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">47-3898435</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">3928 Point Eden Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Hayward</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94545</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">694-6200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">RCUS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-23">2026-05-05</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-24">2026-05-05</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
